T2DM-PGC patients (HbA1c ≥7 %, >53 mmol/mol) showed significantly lower miR-126-3p levels compared with T2DM-GGC subjects (HbA1c <7 %, <53 mmol/mol) (106 T2DM-PGC vs. 87 T2DM-GCC; miR-126-3p a.u.: 0.20±0.15 vs. 0.26±0.26, p=0.04) and with the subset of CTR participants (106 T2DM-PGC vs. 92 CTR; miR-126-3p a.u.: 0.20±0.17 vs 0.34±0.31 vs. p<0.01, Fig. 3), after adjustment for age, platelet count and ApoAI levels. This evidence concerns the gene APOA1 and type 2 diabetes mellitus.